Oncology biotech Prelude guns for $100M IPO

Fierce 15 winner Prelude Therapeutics is going for a $100 million IPO, a pretty common goal for biotechs in 2020, as it looks to finish off early clinical work for its cancer candidate PRT543.

The biotech is targeting PRMT5, an enzyme related to treatment resistance and oncogenesis in both solid and hematological cancers, although it has stayed mum on exact oncologic targets.